ストックスクリーナーアプリを入手
2.04
4.67%
-0.10
プレマーケット:
2.05
0.010
+0.49%
前日終値:
$2.14
開ける：
$2.12
24時間の取引高:
12.00M
Relative Volume:
1.11
時価総額：
$2.01B
収益：
$1.31M
当期純損益:
$-597.65M
株価収益率:
-2.1031
EPS:
-0.97
ネットキャッシュフロー:
$-425.62M
1週間 パフォーマンス:
-10.13%
1か月 パフォーマンス:
-13.56%
6か月 パフォーマンス:
-24.44%
1年 パフォーマンス:
-26.62%
1日の値動き範囲:
$2.03
$2.14
1週間の範囲:
$2.03
$2.25
52週間の値動き範囲:
$1.83
$4.27
Immunitybio Inc Stock (IBRX) Company Profile
IBRX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
IBRX
Immunitybio Inc
|
2.04 | 2.11B | 1.31M | -597.65M | -425.62M | -0.97 |
|
VRTX
Vertex Pharmaceuticals Inc
|
459.78 | 117.45B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
780.50 | 82.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
398.82 | 52.92B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
837.45 | 52.02B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
176.34 | 37.94B | 447.02M | -1.18B | -906.14M | -6.1812 |
Immunitybio Inc Stock (IBRX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-05-20 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2025-03-06 | 開始されました | H.C. Wainwright | Buy |
| 2025-01-10 | 開始されました | BTIG Research | Buy |
| 2023-05-12 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2022-08-03 | 開始されました | Jefferies | Buy |
Immunitybio Inc (IBRX) 最新ニュース
ImmunityBio Founder Dr. Patrick Soon-Shiong Recognized as One of "100 Most Influential People in Oncology in 2025" - Yahoo Finance
Immunitybio amends sale agreement with Jefferies LLCSEC filing - marketscreener.com
ImmunityBio Signs Amendment to Open Market Sale Agreement With Jefferies - TradingView — Track All Markets
ImmunityBio Inc Stock Analysis and ForecastShort-Term Trading Alerts & Outstanding Trading Tips - earlytimes.in
ImmunityBio, Inc.Common Stock (NQ: IBRX - FinancialContent
Latest IBRX Insights: Stock Movement and Corporate Developments - StocksToTrade
ImmunityBio (NASDAQ:IBRX) Shares Down 5.1%Here's What Happened - MarketBeat
3 Growth Companies With Insider Ownership Up To 37% - simplywall.st
ImmunityBio Sees Shift Amid Market Turbulence - timothysykes.com
Analyzing the Surge: ImmunityBio’s Market Impact - StocksToTrade
ImmunityBio (NASDAQ:IBRX) Stock Price Up 8.9%Should You Buy? - MarketBeat
How Investors May Respond To ImmunityBio (IBRX) Bladder Cancer Milestone And EMA Backing For ANKTIVA - Sahm
Can ImmunityBio Inc. stock sustain institutional interestJuly 2025 Snapshot & Fast Moving Trade Plans - ulpravda.ru
Is ImmunityBio Inc. stock vulnerable to regulatory risksQuarterly Profit Review & Free Long-Term Investment Growth Plans - Bölüm Sonu Canavarı
Rate Hike: Can ImmunityBio Inc. (26CA) stock stage a strong rebound this quarterWeekly Profit Analysis & Weekly Consistent Profit Watchlists - moha.gov.vn
Can ImmunityBio Inc. (26CA) stock withstand sector downturnsRate Hike & Weekly Momentum Stock Picks - Улправда
Can ImmunityBio Inc. stock beat market expectations this quarterQuarterly Market Review & Fast Entry High Yield Stock Tips - DonanımHaber
Why hedge funds are buying ImmunityBio Inc. stockJuly 2025 Momentum & Weekly Momentum Stock Picks - DonanımHaber
Stop Loss: Why ImmunityBio Inc. stock could benefit from AI revolutionTrade Volume Report & Fast Gain Stock Tips - Улправда
ImmunityBio: Anktiva Revenue Will Ramp, But Competitive Risks Remain - Seeking Alpha
3 Cancer Stocks to Buy Amid Rapid Advances in Cancer Treatment - Yahoo Finance
ImmunityBio, Moderna among winners of EU drug recommendations this week - MSN
Is ImmunityBio, Inc. (IBRX) the best NASDAQ stock under $10 to buy? - MSN
Is ImmunityBio, Inc. (IBRX) The Best NASDAQ Stock Under $10 to Buy? - Insider Monkey
Jefferies Lifts ImmunityBio Inc. (IBRX) Price Target Following Anktiva European Expansion - Yahoo Finance
ImmunityBio’s HCW9218 study completion: A potential game-changer for pancreatic cancer treatment - MSN
[Form 4] ImmunityBio, Inc. Insider Trading Activity - Stock Titan
ImmunityBio reports encouraging 3-year bladder cancer treatment data - The Pharma Letter
ImmunityBio (NASDAQ: IBRX) director files insider report with no holdings - Stock Titan
ImmunityBio Reports Strong Long-Term Survival Data For Anktiva In Bladder Cancer Study - Sahm
ImmunityBio Reports 96% Three-Year Bladder Cancer Survival With Anktiva Plus BCG - marketscreener.com
ImmunityBio reports promising 3-year bladder cancer treatment data - Investing.com India
ImmunityBio reports promising 3-year bladder cancer treatment data By Investing.com - Investing.com Nigeria
ANKTIVA® with BCG Demonstrates 96% Survival from Bladder Cancer at Three Years with Median Survival Not Yet Reached in BCG-Unresponsive High-Grade Papillary-Only Non-Muscle Invasive Bladder Cancer - Investing News Network
Anktiva® with BCG demonstrates 96% survival from bladder cancer - marketscreener.com
ImmunityBio appoints Bruce Wendel to board - MSN
Assessing ImmunityBio (IBRX) Valuation After EMA Backs Anktiva for BCG‑Unresponsive Bladder Cancer - simplywall.st
ImmunityBio Appoints Bruce Wendel to Board - TipRanks
ImmunityBio, Inc. Appoints Bruce Wendel to the Board, Effective December 12, 2025 - marketscreener.com
[8-K] ImmunityBio, Inc. Reports Material Event | IBRX SEC FilingForm 8-K - Stock Titan
ImmunityBio (NASDAQ:IBRX) Stock Price Down 7.8%Here's Why - MarketBeat
ImmunityBio (IBRX) Stock in Focus on Dec. 15, 2025: EMA’s ANKTIVA Nod, Analyst Targets, and What Comes Next - ts2.tech
Can ImmunityBio Inoculate Its Future With Regulatory Wins? - RTTNews
ImmunityBio Surges On FDA Green Light For Expanded Bladder Cancer Vaccine Access — Retail Buzz Intensifies - MSN
ImmunityBio’s HCW9218 Study Completion: A Potential Game-Changer for Pancreatic Cancer Treatment - TipRanks
Should EMA’s Conditional Nod for ANKTIVA in High-Risk Bladder Cancer Require Action From ImmunityBio (IBRX) Investors? - Yahoo Finance
ImmunityBio, Inc. (NASDAQ:IBRX) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
ImmunityBio (NASDAQ:IBRX) Shares Gap UpHere's Why - MarketBeat
Has The Recent ImmunityBio Share Price Rebound Created An Opportunity In 2025? - Sahm
ImmunityBio (IBRX) climbs 7.76% on Europe expansion - MSN
ImmunityBio (IBRX) Climbs 7.76% on Europe Expansion - Insider Monkey
Immunitybio Inc (IBRX) 財務データ
収益
当期純利益
現金流量
EPS
0.36%
0.72%
大文字化:
|
ボリューム (24 時間):